The new patent allows the company to assess baseline patient characteristics for clinical trial protocols. Credit: Laboratory Stuff.

Integrated clinical development products and services provider Phesi has filed a new patent covering its smart technology that enables precise clinical trial planning and execution.

The enhanced technology, which is an integrated clinical trial design and protocol optimisation platform, enables Phesi’s systems to synthesise global patient data.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It also allows the company to assess baseline patient characteristics for clinical trial protocols.

Phesi founder and CEO Gen Li said: “Phesi’s business model has always been based on providing superior tech and data-enabled clinical development products and services.

“This patent filing is the final key to unlocking the potential for biopharmaceutical companies to change the future of clinical programmes, as the technology is informed by real patient data from comparable trials.

“In addition to reducing the need for post-hoc trial amendments, our integrated platform pinpoints patient populations of any size, type, and location, including for rare diseases.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The enhanced technology features natural language processing and artificial intelligence (AI). It allows drug developers to optimise the design of their clinical trials and reduce the future risks associated with expensive protocol amendments.

FasterCures board member Annalisa Jenkins said: “It is exciting to see how Phesi’s smart technology is improving the productivity and efficiency of clinical research with operational enhancements that fundamentally shift drug development into a higher gear of effectiveness.

“Most importantly, this proprietary technology allows drug companies to expedite delivery of new treatment options to patients in need, leaving no excuse for poorly designed protocols and/or flawed operational planning.”

In July last year, Phesi launched self-service AI-powered tool ClinSite.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact